Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Myeloid-derived-suppressor cells as regulators of the immune system

Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · see citing works

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · see citing works

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789 · see citing works

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · see citing works

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H. M., Valero, V., Assad, L., Poniecka, A. W., Hennessy, B. T., Green, M. C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,655 · see citing works

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., de Azambuja, E., Aura, C. M., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317 · see citing works

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217 · see citing works

Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response

Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847 · see citing works

Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β1

Li, H., Han, Y., Guo, Q., Zhang, M., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.240 · Cited by 777 · see citing works

Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells

Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S. A., Sotomayor, E. M., Padhya, T. A., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 765 · see citing works

Clinical significance of defective dendritic cell differentiation in cancer.

Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699 · see citing works

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

Bunt, S. K., Yang, L.-L., Sinha, P., Clements, V., Leips, J., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 680 · see citing works

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H., & Middleton, G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 574 · see citing works

Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells

Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527 · see citing works

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342 · see citing works

IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients

Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion‐Sileni, V., D, S. M. M., Zanon, A., Rossi, C. R., Nitti, D., Bronte, V., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803831 · Cited by 302 · see citing works

Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer

Wesolowski, R., Markowitz, J., & Carson, W. E. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-10 · Cited by 291 · see citing works

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival

Scholl, S., Pierga, J., Asselain, B. J. R., Beuzeboc, P., Dorval, T., García-Giralt, E., Jouve, M., Palangié, T., Remvikos, Y., Durand, J. C., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00454-8 · Cited by 152 · see citing works

Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease

Markowitz, J., Brooks, T., Duggan, M. C., Paul, B. K., Pan, X. J., Wei, L., Abrams, Z. B., Luedke, E. A., Lesinski, G. B., Mundy-Bosse, B. L., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1618-8 · Cited by 126 · see citing works

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy

Mundy-Bosse, B. L., Young, G. S., Bauer, T. M., Binkley, E. M., Bloomston, M., Bill, M. A., Bekaii‐Saab, T., Carson, W. E., & Lesinski, G. B. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1029-z · Cited by 121 · see citing works

Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

Sikov, W. M., Berry, D., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Somlo, G., Port, E., Qamar, R., Sturtz, K. B., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s2-05 · Cited by 85 · see citing works

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy

Wu, X., Feng, Q., Wang, Y., Shi, J., Ge, H., & Di, W. J. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0749-9 · Cited by 81 · see citing works

Multiparametric Flow Cytometric Analysis of Inter-Patient Variation in STAT1 Phosphorylation Following Interferon Alfa Immunotherapy

Lesinski, G. B., Kondadasula, S., Crespin, T. R., Shen, L., Kendra, K. L., Walker, M. J., & Carson, W. E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh252 · Cited by 75 · see citing works

Contribution of the immune system to the chemotherapeutic response

McDonnell, A. M., Nowak, A. K., & Lake, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0246-z · Cited by 34 · see citing works

Elevated Circulating Myeloid Derived Suppressor Cells (MDSC) Are Associated with Inferior Overall Survival (OS) and Correlate with Circulating Tumor Cells (CTC) in Patients with Metastatic Breast Cancer.

Cole, S., Montero, A. J., Garret-Mayer, E., Onicescu, G., Vandenberg, T., Hutchens, S., & Diaz-Montero, C. M. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-4135 · Cited by 24 · see citing works

Neoadjuvant therapy for breast cancer: Assessing treatment progress and managing poor responders

Wesolowski, R., & Budd, G. T. (2008) · Current Oncology Reports · doi:10.1007/s11912-009-0007-5 · Cited by 8 · see citing works

Abstract P4-09-18: Characterization of circulating myeloid derived suppressor cells and cytokines in patients undergoing neo-adjuvant chemotherapy for breast cancer

Wesolowski, R., Duggan, M. C., Stiff, A. R., Trikha, P., Schoenfield, L. R., Abdel‐Rasoul, M., Layman, R. M., Ramaswamy, B., Macrae, E. R., Lustberg, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p4-09-18 · Cited by 2 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349 · see citing works

Systemic immunity in cancer

Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400 · see citing works

Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner

Bayık, D., Zhou, Y., Park, C., Hong, C., Vail, D. J., Silver, D. J., Lauko, A. J., Roversi, G. A., Watson, D. C., Lo, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1355 · Cited by 246 · see citing works

The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications

Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., & Sasaki, H. (2019) · Medical Oncology · doi:10.1007/s12032-019-1329-2 · Cited by 229 · see citing works

Chemo-Immunotherapy: A New Trend in Cancer Treatment

Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Martínez‐Pérez, A., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Cancers · doi:10.3390/cancers15112912 · Cited by 183 · see citing works

Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy

İmani, S., Farghadani, R., Roozitalab, G., Maghsoudloo, M., Emadi, M., Moradi, A., Abedi, B., & Kaboli, P. J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03394-8 · Cited by 108 · see citing works

Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation

Zheng, H., Siddharth, S., Parida, S., Wu, X., & Sharma, D. (2021) · Cancers · doi:10.3390/cancers13133357 · Cited by 93 · see citing works

Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells

Dean, M. J., Ochoa, J. B., Sanchez‐Pino, M. D., Zabaleta, J., Garai, J., Valle, L. D., Wyczechowska, D. D., Baiamonte, L. B., Philbrook, P., Majumder, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695972 · Cited by 85 · see citing works

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy

Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 70 · see citing works

Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment

Belderbos, R. A., Aerts, J. G. J. V., & Vroman, H. H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.03.007 · Cited by 67 · see citing works

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

Bergenfelz, C., Roxå, A., Mehmeti, M., Leandersson, K., & Larsson, A.-M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02472-z · Cited by 67 · see citing works

Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients

Kobayashi, M., Chung, J., Beg, M. S., Arriaga, Y. E., Verma, U. N., Courtney, K. D., Mansour, J. C., Haley, B., Khan, S. A., Horiuchi, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0330 · Cited by 64 · see citing works

The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression

Kim, G., Pastoriza, J. M., Condeelis, J. S., Sparano, J. A., Filippou, P. S., Karagiannis, G. S., & Oktay, M. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01022 · Cited by 56 · see citing works

Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression

Sica, A., Guarneri, V., & Gennari, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.197 · Cited by 56 · see citing works

MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target

Liu, H., Wang, Z., Yuntao, Z., & Yang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199273 · Cited by 52 · see citing works

Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers

Tan, W., Yang, M. W., Yang, H., Zhou, F., & Shen, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174435 · Cited by 49 · see citing works

How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review

Merlano, M. C., Denaro, N., Galizia, D., Ruatta, F., Occelli, M., Minei, S., Abbona, A., Paccagnella, M., Ghidini, M., & Garrone, O. (2022) · Biomedicines · doi:10.3390/biomedicines10081822 · Cited by 48 · see citing works

Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside

Roy, S., Sethi, T. K., Taylor, D., Kim, Y. J., & Johnson, D. B. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0420-585rr · Cited by 42 · see citing works

Implications of metabolism-driven myeloid dysfunctions in cancer therapy

Strauss, L., Guarneri, V., Gennari, A., & Sica, A. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00556-w · Cited by 38 · see citing works

Role of myeloid-derived suppressor cells in metastasis

Cole, K., Pravoverov, K., & Talmadge, J. E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09947-x · Cited by 38 · see citing works

Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice

Zhang, J., Pan, S., Chen, J., Li, H., Dong, J., Sun, Q., Jin, H., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.819405 · Cited by 35 · see citing works

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer

Liu, S., Li, J., Gu, L., Wu, K.-Z., & Hua, X. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s388075 · Cited by 35 · see citing works

Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients

Valdés-Ferrada, J., Muñoz‐Durango, N., Pérez‐Sepúlveda, A., Muñiz, S., Coronado-Arrázola, I., Francisco Acevedo, C., Soto, J. A., Bueno, S. M., Sanchez, C. G., & Kalergis, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01413 · Cited by 34 · see citing works

The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells

Sánchez-León, M. L., Jiménez‐Cortegana, C., Cabrera, G., Vermeulen, E. M., de la Cruz‐Merino, L., & Sánchez‐Margalet, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050484 · Cited by 34 · see citing works

Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study

Wang, X., Cang, W., Liu, X., Cheng, Y., Wan, X., Feng, F., Ren, T., Zhao, J., Jiang, F., Cheng, H., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101974 · Cited by 32 · see citing works

Importance of myeloid derived suppressor cells in cancer from a biomarker perspective

Kalathil, S. G., & Thanavala, Y. M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104280 · Cited by 32 · see citing works

Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer

Kim, R., & Kin, T. (2021) · Cancers · doi:10.3390/cancers13194756 · Cited by 30 · see citing works

The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery

Batalha, S., Cristóvão‐Ferreira, S., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13061305 · Cited by 30 · see citing works

Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer

Larsson, A.-M., Roxå, A., Leandersson, K., & Bergenfelz, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-49943-y · Cited by 28 · see citing works

Role of myeloid-derived suppressor cells in tumor recurrence

Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10079-1 · Cited by 28 · see citing works

Myeloid-derived suppressor cells and their role in gynecological malignancies

Mabuchi, S., Yokoi, E., Komura, N., & Kimura, T. (2018) · Tumor Biology · doi:10.1177/1010428318776485 · Cited by 28 · see citing works

Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives

Rajkumari, S., Singh, J., Agrawal, U., & Agrawal, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112949 · Cited by 28 · see citing works

Transforming growth f actor‐beta1 and m yeloid‐derived suppressor cells: A cancerous partnership

Mojsilović, S. B., Mojsilović, S. S., Bjelica, S., & Santibanez, J. F. (2021) · Developmental Dynamics · doi:10.1002/dvdy.339 · Cited by 26 · see citing works

In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid‐Derived Suppressor Cells

Duarte‐Sanmiguel, S., Panic, A., Dodd, D. J., Salazar‐Puerta, A. I., Moore, J. T., Lawrence, W. R., Nairon, K. G., Francis, C., Zachariah, N., McCoy, W., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101619 · Cited by 20 · see citing works

Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy

Wang, X., & Jing, J. (2025) · MedComm · doi:10.1002/mco2.70346 · Cited by 19 · see citing works

Increased levels of myeloid-derived suppressor cells in esophageal cancer patients is associated with the complication of sepsis

Xu, J., Peng, Y., Yang, M., Guo, N., Liu, H., Gao, H., Niu, F., Wang, R., Wang, C., & Yu, K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109864 · Cited by 16 · see citing works

Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

Wesolowski, R., Stiff, A. R., Quiroga, D. M., McQuinn, C. W., Li, Z., Nitta, H., Savardekar, H., Benner, B. N., Ramaswamy, B., Lustberg, M. B., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06949-4 · Cited by 16 · see citing works

Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction

Álvarez-Arzola, R., Oliver, L., Valdés, A. F.-C., & Mesa, C. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.05.001 · Cited by 16 · see citing works

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

Qian, X., Wang, H., & Yan, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963533 · Cited by 14 · see citing works

Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression

Seo, E., Namgung, J. H., Oh, C.-S., Kim, S., & Lee, S. H. (2018) · Immune Network · doi:10.4110/in.2018.18.e23 · Cited by 14 · see citing works

Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment

Zhang, C., Liu, W., Yang, P., Lin, R., Pu, L., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1654947 · Cited by 13 · see citing works

Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications

Zhou, Z., Zhong, H., Wang, H., Wang, S., Kridis, W. B., Wang, R., Shen, K., Wang, Z., & Huang, R. (2025) · Discover Oncology · doi:10.1007/s12672-025-03797-1 · Cited by 13 · see citing works

Myeloid-Derived Suppressor Cells (MDSCs) at the Crossroad of Senescence and Cancer

Talarico, G., Orecchioni, S., Falvo, P., & Bertolini, F. (2025) · Cancers · doi:10.3390/cancers17132251 · Cited by 12 · see citing works

Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Savardekar, H., Allen, C., Jeon, H., Li, J., Quiroga, D. M., Schwarz, E. J., Wu, R. C. H., Zelinskas, S., Lapurga, G., Abreo, A., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0572 · Cited by 11 · see citing works

Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival

Fallah, J., Diaz-Montero, C. M., Rayman, P. A., Wei, W., Finke, J. H., Kim, J. S., Pavicic, P. G., Lamenza, M., Dann, P., Stephenson, A. J., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.03.004 · Cited by 11 · see citing works

The roles of polymorphonuclear myeloid-derived suppressor cells in endometriosis

Satake, E., Koga, K., Takamura, M., Izumi, G., Elsherbini, M., Taguchi, A., Makabe, T., Takeuchi, A., Harada, M., Hirata, T., et al. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103371 · Cited by 11 · see citing works

Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy

Lafrenie, R. M., Speigl, L., Buckner, C. A., Pawelec, G., Conlon, M., & Shipp, C. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.002 · Cited by 9 · see citing works

Integrative Pharmacology: Advancing Development of Effective Immunotherapies

Tabrizi, M. A., Zhang, D., Ganti, V., & Azadi, G. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0229-2 · Cited by 9 · see citing works

Inhibition of Bruton’s tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors

Schwarz, E. J., Benner, B. N., Wesolowski, R., Quiroga, D. M., Good, L., Sun, S. H., Savardekar, H., Li, J., Jung, K. J., Duggan, M. C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.169927 · Cited by 8 · see citing works

Targeting adenosine receptor 2B in triple negative breast cancer

Neumann, C. A., Levine, K. M., & Oesterreich, S. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.60 · Cited by 8 · see citing works

Comments on the ambiguity of selected surface markers, signaling pathways and omics profiles hampering the identification of myeloid-derived suppressor cells

Lutz, M. B., & Eckert, I. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104347 · Cited by 7 · see citing works

Developmental pathways of myeloid-derived suppressor cells in neoplasia

Abrams, S. I. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104261 · Cited by 7 · see citing works

Granulocytic myeloid-derived suppressor cells correlate with outcomes undergoing neoadjuvant chemotherapy for bladder cancer

Yang, G., Liu, M., Liu, Q., Duan, X., Chen, H., Zhang, L., & Bo, J. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.06.009 · Cited by 6 · see citing works

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy

Wang, B. G., Yao, Y., Huang, H., Zhou, J., & Ni, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1131259 · Cited by 6 · see citing works

A Novel Neutrophil Extracellular Trap Signature Predicts Patient Chemotherapy Resistance and Prognosis in Lung Adenocarcinoma

Xing, L., Wu, S., Xue, S., & Li, X. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01170-1 · Cited by 5 · see citing works

Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumours

Xue, J., Xia, Y., Ding, Q., Li, N., Wu, M., & Song, J. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2282181 · Cited by 5 · see citing works

Subtype-specific heterogeneity of myeloid-derived suppressor cells in breast cancer: current insights and future directions

Gong, B., & Zheng, L. (2026) · PeerJ · doi:10.7717/peerj.20937 · Cited by 4 · see citing works

Plasma Cytokine Levels and Cytokine Genetic Polymorphisms in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy

Lafrenie, R. M., Bewick, M. A., Buckner, C. A., & Conlon, M. (2023) · Immuno · doi:10.3390/immuno3010002 · Cited by 4 · see citing works

Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics

Wu, Q., Yang, J.-W., Zhang, D., Xu, H.-W., Yu, Y., & Zheng, Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-03028-1 · Cited by 2 · see citing works

Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy

Hu, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00010-2 · Cited by 2 · see citing works

Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients

Cole, K., Ly, Q. P., Hollingsworth, M. A., Cox, J. L., Fisher, K. W., Padussis, J. C., Foster, J. M., Vargas, L. M., & Talmadge, J. E. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108628 · Cited by 2 · see citing works

Myeloid-Derived Suppressive Cells in Ageing and Age-Related Diseases

Bueno, V., & Pawelec, G. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-87532-9_4 · Cited by 1 · see citing works

The Effects Of Myeloid-Derived Suppressor Cells On Cancer And Cancer Treatments

Wesolowski, R. (2018) · Science Trends · doi:10.31988/scitrends.11898

Immunological Effects of Conventional Anticancer Drugs

Garrone, O., Denaro, N., Paccagnella, M., Abbona, A., & Merlano, M. C. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_340-1

Emerging Biomarkers of Response to Immunotherapy: Host Characteristics in Breast Cancer

Mathesh, V., & Reddy, S. M. (2025) · Cancer immunotherapy · doi:10.1007/13905_2024_44

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment

Kant, R., Roy, P., Kaur, A., & Kumar, R. (2025) · Journal of Coloproctology · doi:10.1055/s-0045-1809675

Immunological Effects of Conventional Anticancer Drugs

Garrone, O., Denaro, N., Paccagnella, M., Abbona, A., & Merlano, M. C. (2025) · Springer eBooks · doi:10.1007/978-3-032-00775-9_340

Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer

Kanaoka, H., Nagahashi, M., Tsuchida, J., Kuroiwa, M., Urano, S., Komatsu, M., Yoshida, S., Oshiro, A., Sugimoto, G., Mitsuyoshi, A., et al. (2026) · Breast Cancer · doi:10.1007/s12282-026-01831-w

Effet anti-tumoral du GTN +/- doxorubicine dans le cancer du sein triple négatif : implication du système immunitaire

Mabrouk, N. (2021) · theses.fr (ABES) · doi:10.70675/8ef700b1zdb78z4da6z9da1zde8ca3e4700b

Abstract P4-09-18: Characterization of circulating myeloid derived suppressor cells and cytokines in patients undergoing neo-adjuvant chemotherapy for breast cancer

Wesolowski, R., Duggan, M. C., Stiff, A. R., Trikha, P., Schoenfield, L. R., Abdel‐Rasoul, M., Layman, R. M., Ramaswamy, B., Macrae, E. R., Lustberg, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p4-09-18 · Cited by 2 · see citing works

Study of circulating myeloid derived suppressor cells (MDSC) in patients with breast cancer undergoing neo-adjuvant chemotherapy; interim results

Wesolowski, R., Markowitz, J., Paul, B. K., Carothers, S., Abdel‐Rasoul, M., & Carson, W. E. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-s1-p66 · Cited by 2 · see citing works

Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy

Talmadge, J. E., Reed, E., Cowan, K. H., Gabrilovich, D. I., Warkentin, P., Janssen, W. E., Wisecarver, J. L., Anderson, J., Mailliard, M., Maas, S. A., et al. (2008) · Blood · doi:10.1182/blood.v112.11.4653.4653

Circulating myeloid‐derived suppressor cells: An independent prognostic factor in patients with breast cancer

Safarzadeh, E., Hashemzadeh, S., Duijf, P. H. G., Mansoori, B., Khaze, V., Mohammadi, A., Kazemi, T., Yousefi, M., Asadi, M., Mohammadi, H., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26896 · Cited by 85 · see citing works

Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort.

Carrión, N. P., Jiménez‐Cortegana, C., Holgado, E., Jurado, J. C., Romero, J. L. A., León, M. L. S., Margalet, V. S., Nogales, E., Antón, F. M., Quiroga, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2543 · Cited by 1 · see citing works